Determinants of pharmaceutical product price MCQs With Answer help B. Pharm students master drug pricing fundamentals. Understanding determinants of pharmaceutical product price is essential for students entering industry, regulatory affairs, or pharmacy practice. This guide explains key factors — cost of production, raw materials, manufacturing efficiency, supply chain, market demand, competition, patent status, regulatory policies, reimbursement systems, pharmacoeconomics, and ethical pricing — that influence pricing decisions. Grasping concepts like marginal cost, price elasticity, reference pricing, and price controls enables analysis of real-world strategies and policy impacts. Familiarity with these determinants supports formulary decisions, pharmacoeconomic evaluations, and patient access considerations. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. Which component is a variable cost directly impacting the marginal cost of producing an additional tablet?
- Factory rent
- Active pharmaceutical ingredient (API) cost
- Depreciation of equipment
- Regulatory filing fees
Correct Answer: Active pharmaceutical ingredient (API) cost
Q2. Cost-plus pricing primarily bases the drug price on which of the following?
- Perceived therapeutic value to patients
- Cost of production plus a fixed markup
- Competing product prices in the market
- Health technology assessment (HTA) outcomes
Correct Answer: Cost of production plus a fixed markup
Q3. Price elasticity of demand for a life-saving patented drug is typically:
- Highly elastic
- Perfectly elastic
- Relatively inelastic
- Unit elastic
Correct Answer: Relatively inelastic
Q4. Which pricing strategy sets price according to the therapeutic benefit and outcomes rather than costs?
- Cost-plus pricing
- Value-based pricing
- Marginal cost pricing
- Penetration pricing
Correct Answer: Value-based pricing
Q5. Reference pricing systems influence pharmaceutical prices by:
- Setting global uniform prices for all medicines
- Benchmarking reimbursement to prices in a basket of comparator countries or drugs
- Mandating a fixed markup for wholesalers
- Forbidding generic substitution
Correct Answer: Benchmarking reimbursement to prices in a basket of comparator countries or drugs
Q6. Which factor most typifies a long-term determinant that can reduce unit cost through increased production?
- Patent expiration
- Economies of scale
- Short-term raw material shortage
- One-time regulatory inspection fee
Correct Answer: Economies of scale
Q7. Which of the following regulatory mechanisms directly limits the maximum price a manufacturer can charge?
- Price control (price ceiling)
- Patent protection
- Market exclusivity
- Reimbursement listing
Correct Answer: Price control (price ceiling)
Q8. In tender-based procurement, the main determinant that drives the awarded price is:
- Manufacturer’s royalty to inventors
- Lowest responsive bid meeting specifications
- Retail pharmacist markup
- Reference price in another country
Correct Answer: Lowest responsive bid meeting specifications
Q9. What is the likely effect of generic entry on originator drug pricing in a competitive market?
- Originator price increases due to brand loyalty
- Originator price remains unchanged
- Originator price decreases due to competition
- Originator becomes price-controlled by regulators
Correct Answer: Originator price decreases due to competition
Q10. Which pharmacoeconomic measure is commonly used to compare cost per health outcome and inform pricing decisions?
- Gross profit margin
- Quality-adjusted life year (QALY) cost-effectiveness
- Inventory turnover ratio
- Average wholesale price
Correct Answer: Quality-adjusted life year (QALY) cost-effectiveness
Q11. Differential (tiered) pricing aims to:
- Charge the same price globally
- Charge higher prices to low-income countries
- Set prices according to each market’s ability to pay
- Eliminate patents to reduce prices
Correct Answer: Set prices according to each market’s ability to pay
Q12. Which supply-chain factor can suddenly increase the finished product price even if manufacturing costs are stable?
- Long-term economies of scale
- Shortage of key raw materials due to global disruption
- Fixed administrative overheads
- Depreciation schedule
Correct Answer: Shortage of key raw materials due to global disruption
Q13. The presence of markups at multiple distribution levels (manufacturer, wholesaler, retailer) typically results in:
- Lower patient price versus ex-factory price
- Higher final retail price borne by the patient
- No change in consumer price
- Guaranteed affordability
Correct Answer: Higher final retail price borne by the patient
Q14. Which pricing approach is most affected by currency fluctuations and import tariffs?
- Locally manufactured product priced in local currency
- Imported API-dependent drug priced in local market
- Value-based priced biologic with domestic production
- Price controlled essential medicines produced locally
Correct Answer: Imported API-dependent drug priced in local market
Q15. Health Technology Assessment (HTA) primarily influences price by:
- Determining manufacturing costs
- Evaluating clinical effectiveness and cost-effectiveness to guide reimbursement
- Setting wholesale margins
- Controlling raw material supply
Correct Answer: Evaluating clinical effectiveness and cost-effectiveness to guide reimbursement
Q16. A manufacturer uses a higher price during product launch to recover R&D costs expecting lower demand later. This strategy is called:
- Penetration pricing
- Skimming pricing
- Marginal cost pricing
- Cost-plus pricing
Correct Answer: Skimming pricing
Q17. Which of the following most directly reduces the per-unit cost for a manufacturer over time?
- Increasing fixed costs
- Learning curve and process optimization
- Short-term promotional discounts
- Higher regulatory fees
Correct Answer: Learning curve and process optimization
Q18. Price transparency policies in pharmaceuticals are intended to:
- Hide negotiated discounts from payers
- Improve competition and inform purchasers
- Prevent generic entry
- Increase administrative burden without benefit
Correct Answer: Improve competition and inform purchasers
Q19. Which cost is amortized over units produced and thus decreases per unit as production increases?
- Variable raw material cost
- Fixed capital investment (equipment)
- Per-batch quality testing fee
- Per-unit packaging cost
Correct Answer: Fixed capital investment (equipment)
Q20. When a biosimilar enters the market, the primary pricing pressure on the reference biologic comes from:
- Identical manufacturing cost structures
- Therapeutic substitution and insurer bargaining
- Government-imposed subsidies for the reference biologic
- Increased R&D spending by the originator
Correct Answer: Therapeutic substitution and insurer bargaining
Q21. Which tax or fee directly increases patient out-of-pocket price at retail level?
- Corporate income tax paid by a manufacturer
- Wholesale-to-retail VAT or sales tax applied at point of sale
- Patent filing fee
- Research grant disbursement
Correct Answer: Wholesale-to-retail VAT or sales tax applied at point of sale
Q22. Price negotiations between a manufacturer and a national payer often use which data to justify a lower price?
- Manufacturer’s confidential profit margins only
- Real-world effectiveness, budget impact analysis, and comparator costs
- Number of manufacturing sites globally
- Length of time since drug discovery
Correct Answer: Real-world effectiveness, budget impact analysis, and comparator costs
Q23. Parallel importation can influence national prices by:
- Reducing cross-border competition
- Allowing lower-priced versions from other markets to be sold domestically
- Increasing patent term
- Raising manufacturing costs
Correct Answer: Allowing lower-priced versions from other markets to be sold domestically
Q24. Orphan drug incentives (e.g., exclusivity) typically affect price by:
- Lowering prices due to mass production
- Enabling higher prices because of limited patient populations and exclusivity
- Forcing immediate generic competition
- Standardizing prices across indications
Correct Answer: Enabling higher prices because of limited patient populations and exclusivity
Q25. Which metric helps a manufacturer set launch price by estimating how much payers will accept per unit of health gain?
- Break-even point in units sold
- Cost-effectiveness threshold (willingness-to-pay per QALY)
- Number of production batches per year
- Inventory turnover days
Correct Answer: Cost-effectiveness threshold (willingness-to-pay per QALY)
Q26. A retail pharmacy’s final consumer price is most immediately affected by which of the following?
- Manufacturer’s R&D pipeline
- Wholesale acquisition cost plus pharmacy markup and taxes
- Global patent landscape
- International reference pricing only
Correct Answer: Wholesale acquisition cost plus pharmacy markup and taxes
Q27. Which is a common industry response to strict price controls that limit profitability?
- Increased investment in price-controlled products
- Withdrawal from the market or reduced supply
- Immediate lowering of R&D budgets globally
- Raising patent durations legally
Correct Answer: Withdrawal from the market or reduced supply
Q28. In value-based contracts between manufacturers and payers, payment may be linked to:
- List price regardless of outcome
- Real-world patient outcomes and performance metrics
- Manufacturer’s total global sales only
- Number of clinical trials conducted
Correct Answer: Real-world patient outcomes and performance metrics
Q29. The term “ex-factory price” refers to:
- The price paid by the final consumer including taxes
- The price of the product when sold by the manufacturer before distribution markups
- The wholesale price plus pharmacy margin
- The international reference price only
Correct Answer: The price of the product when sold by the manufacturer before distribution markups
Q30. Which factor encourages lower drug prices through stimulating competition after patent expiry?
- Market exclusivity extensions
- Speedy regulatory approval pathways for generics and biosimilars
- Imposing price floors
- Increased tariffs on imported generics
Correct Answer: Speedy regulatory approval pathways for generics and biosimilars
